What does this research mean for the field?

Photobiomodulation therapy significantly improves cognitive deficits and ameliorates key pathologies in animal models of Alzheimer's disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This meta-analysis aims to evaluate the effectiveness and underlying mechanisms of photobiomodulation therapy in animal models of Alzheimer’s disease.

March 2, 2026Open Access

Effect and potential mechanism of photobiomodulation therapy on cognitive deficits in animal models of Alzheimer’s disease: a systematic review and meta-analysis

Key Points

This meta-analysis aims to evaluate the effectiveness and underlying mechanisms of photobiomodulation therapy in animal models of Alzheimer’s disease.
Systematic review of existing studies on photobiomodulation therapy and cognitive deficits in Alzheimer’s models.
Meta-analysis conducted to assess the overall efficacy of the intervention on cognitive performance.
Evaluation of mechanisms involving oxidative stress and mitochondrial function.
Photobiomodulation significantly improves cognitive function in animal models of Alzheimer’s disease.
The therapy appears to reduce oxidative stress and enhance mitochondrial function.
Strong preclinical evidence supports the efficacy, though translation to human applications requires further investigation.

Abstract

This meta-analysis demonstrates that PBM has significant therapeutic potential for AD animal models by improving cognition and ameliorating key pathologies. The mechanisms likely involve mitigating oxidative stress and enhancing mitochondrial function. While preclinical evidence strongly supports the efficacy of PBM, translation to humans requires careful optimization of treatment parameters and dose-response relationships. Further high-quality preclinical trials are crucial to validate the therapeutic potential of PBM for AD.

Bookmark

View Full Paper